Considerable evidence has indicated that accumulation of reactive oxygen species (ROS) and consequent oxidative stress are important contributors to cardiometabolic disorders including diabetes, non-alcoholic fatty liver disease, atherosclerosis, ischemic heart injury, diabetic cardiomyopathy, and congestive heart failure. However, blanket antioxidant therapies to combat cardiometabolic disease have not generally yielded favourable results.

The current state of uncertainty concerning the feasibility of antioxidant therapy is partly due to the incomplete knowledge regarding oxidant/antioxidant turnover and their interaction with physiologically important molecular pathways in the organism. Nuclear receptors (NRs) constitute an important molecular network playing pivotal roles in multiple cellular processes and represent the second largest group of drug targets. Emerging data indicate that NRs are important players in cardiometabolic disease, and interaction between NRs and ROS exists. Certain NRs are involved in regulating oxidant/antioxidant turnover at the transcriptional level. Conversely, NR levels could be regulated by ROS. Continuous efforts are warranted for a better understanding of the NRs-ROS interaction in the pathogenesis of cardiometabolic disease, aiming for the identification of specific targets for modulation of oxidative stress and treatment of cardiometabolic disease.

The aim of this Special Issue is to stimulate efforts to understand the crosstalk between nuclear receptors and ROS, and their roles in cardiometabolic disease suffering from oxidative stress. Both original research articles and review articles discussing the current state of the art are welcome.

Potential topics include but are not limited to the following:

• Role of NRs and oxidative stress in cardiometabolic diseases, such as diabetes, non-alcoholic fatty liver disease, atherosclerosis, arterial aneurysm, ischemic heart disease, cardiac hypertrophy, heart failure, diabetic cardiomyopathy, and pulmonary hypertension
• Identification of NRs-regulated signalling pathways implicated in ROS/antioxidant turnover in the pathophysiology of the above-mentioned diseases
• Identification of NRs-targeted molecules with therapeutic potential to manipulate oxidative stress in the treatment of the above-mentioned diseases
• Recent advances in NRs-ROS interaction in physiological/pathophysiological conditions, with a focus in the pathogenesis of cardiometabolic disease